MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new therapies, however, few mouse models represent the complexity of TNBC. Here, we develop a female TNBC murine model by mimicking two common TNBC mut...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 5665 - 21
Main Authors Doha, Zinab O., Wang, Xiaoyan, Calistri, Nicholas L., Eng, Jennifer, Daniel, Colin J., Ternes, Luke, Kim, Eun Na, Pelz, Carl, Munks, Michael, Betts, Courtney, Kwon, Sunjong, Bucher, Elmar, Li, Xi, Waugh, Trent, Tatarova, Zuzana, Blumberg, Dylan, Ko, Aaron, Kirchberger, Nell, Pietenpol, Jennifer A., Sanders, Melinda E., Langer, Ellen M., Dai, Mu-Shui, Mills, Gordon, Chin, Koei, Chang, Young Hwan, Coussens, Lisa M., Gray, Joe W., Heiser, Laura M., Sears, Rosalie C.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 13.09.2023
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new therapies, however, few mouse models represent the complexity of TNBC. Here, we develop a female TNBC murine model by mimicking two common TNBC mutations with high co-occurrence: amplification of the oncogene MYC and deletion of the tumor suppressor PTEN . This Myc;Ptenfl model develops heterogeneous triple-negative mammary tumors that display histological and molecular features commonly found in human TNBC. Our research involves deep molecular and spatial analyses on Myc;Ptenfl tumors including bulk and single-cell RNA-sequencing, and multiplex tissue-imaging. Through comparison with human TNBC, we demonstrate that this genetic mouse model develops mammary tumors with differential survival and therapeutic responses that closely resemble the inter- and intra-tumoral and microenvironmental heterogeneity of human TNBC, providing a pre-clinical tool for assessing the spectrum of patient TNBC biology and drug response. Few mouse models recapitulate the complexity of triple negative breast cancer (TNBC). Here, the authors develop and characterise a TNBC mouse model harbouring two common TNBC mutations: amplification of the oncogene MYC and deletion of the tumour suppressor PTEN.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-40841-6